Pablo Legorreta, Royalty Pharma CEO (Patrick T. Fallon/Bloomberg via Getty Images)
Royalty Pharma execs shed light on strategy behind their first gene therapy deal
A deal with Ferring Pharmaceuticals last month represented Royalty Pharma’s first foray into gene therapy royalties, and it’s already raising questions about whether it represents …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
